BMX-101 targets CD38 & PD-L1 and is expected to elicit anti-CD38 cytotoxic activity, while simultaneously activating the immune system by blocking PD-L1, an immune checkpoint, at the site of the tumor, thereby increasing the therapeutic index and efficacy in patients. In 2018, the Nobel prize for Medicine was awarded to an approach based on antibodies that blocked the PDL1/PD1 immune checkpoint axis. During the ASCO congress (American Society of Clinical Oncology), several studies regularly show high therapeutic efficacy of these approaches. BMX-101 is advancing through preclinical studies for treatment of hematological malignancies (multiple myeloma) & solid tumors (hepatocarcinoma).  

BMX-002 targets EGFR and anti-HER2 receptors. This BiXAb<sup><span style= »font-size: medium; »>®</span></sup> allowed the validation of the BiXAb<sup><span style= »font-size: medium; »>®</span></sup> platform technology demonstrating a superior efficacy versus the combination of the monoclonal parental antibodies and a synergistic activity of the individual monospecific Abs. BMX-002 also demonstrated the POC for the synergistic targeting of EGFR and HER2 and is currently being evaluated in several preclinical models. 

BMX-101 and BMX-002 programs have demonstrated the superior value of the BiXAb<sup><span style= »font-size: medium; »>®</span></sup> technology: rapid production, quick generation of the IP covering the molecule, excellent drug like properties, manufacturability and CoGs, and finally versatility and multi-specific capabilities (eg. Trispecific antibodies). 

Other development programs (e.g. BMX-501, BMX-401) are underway. One of them explores a novel approach to T Cell redirection, which is not based on redirecting of all CD3+ T cells; this strategy may result in a major advancement in the immunotherapy of cancers for both solid tumors and hematological malignancies. Several patent family applications have been filed to protect such disruptive approaches. 

Biomunex is also evaluating other discovery programs focused on innovative targets or pairs of targets (e.g. BMX-003) that should become breakthrough immunotherapies in the future.